A friend once described picking a weight-loss telehealth service as “ordering off a menu where half the dishes don’t exist yet.” That was two years ago. Today the market is bigger, messier, and shaped by a wave of FDA warning letters and a legal settlement that pushed several major brands off compounded semaglutide entirely. If you started researching six months ago, half of what you read is already out of date.
This guide cuts through that. Twelve real services, real prices, honest tradeoffs.
What Actually Matters When You’re Comparing These
Four things separate a service worth trusting from one worth skipping.
Price transparency. Can you see the per-vial or per-month medication cost before you hand over a credit card? Many platforms bundle a membership fee on top of medication, making the true cost invisible until step four of checkout.
Clinical oversight. Is a licensed physician actually reviewing your intake, or is an algorithm waving you through? Ongoing monitoring matters more than the initial consult.
Pharmacy sourcing. For compounded meds, does the service name a specific pharmacy and provide batch-level testing documents? Generic “certificates of analysis” are not the same as published per-product purity numbers.
Shipping reliability. GLP-1 injectables need cold-chain handling. Does the service offer it, and is it included in the price?
The 12 Services
1. FormBlends
Most GLP-1 telehealth services do one thing: get you on semaglutide or tirzepatide and stop there. FormBlends built a different model. The intake is online, a licensed physician signs off on the prescription, and the medication ships from a 503A compounding pharmacy that runs cGMP and FDA-inspected processes. It covers 47 states with cold-chain shipping at no added charge.
The part that sets it apart from every other name on this list is scope. Compounded semaglutide is $299 per vial and tirzepatide is $349. Those prices are visible on the site before you create an account, with no membership fee layered underneath. Compare that to Ro, where the platform membership and medication are billed as separate line items. FormBlends also carries liraglutide at $199 and retatrutide at $389, plus a full catalog of compounded peptides including BPC-157, NAD+, and growth hormone secretagogues, all under the same physician-supervised roof. That catalog comes with published purity figures per product, confirmed by HPLC, mass spectrometry, and endotoxin testing on each batch. Semaglutide batches publish at 99.1% purity; tirzepatide at 99.3%.
One clear-eyed note: compounded medications are not FDA-approved finished drugs, and most peptides outside the GLP-1 class have limited human clinical data. This is not a plug-and-play situation. But for someone who wants a single clinically supervised source for a weight-loss protocol plus adjunct therapies, no other platform on this list comes close in range.
2. Hims and Hers
Hims and Hers is one of the most recognized names in telehealth, and after a settlement with Novo Nordisk took effect in March 2026, the platform moved new weight-loss patients onto branded medications. Injectable Wegovy runs about $299 per month through the platform; oral Wegovy around $249. Zepbound is listed at roughly $399. For patients with commercial insurance plus a savings card, branded costs can drop to nearly nothing. The app is polished and onboarding is fast. The tradeoff is that you are now locked into branded pricing and availability, which can be inconsistent depending on pharmacy stock.
3. Ro Body
Ro separates its platform membership from medication costs, which is worth knowing upfront. The first month runs about $39, then roughly $149 month-to-month or as low as $74 monthly on an annual prepay. Medication is billed on top of that. Ro has a dedicated prior-authorization team, which makes it a genuine option for patients who want help getting branded meds covered by insurance rather than paying cash for compounded versions. The experience is well-organized and the support staff is responsive. Just do the math on total monthly spend before committing.
4. Mochi Health
Mochi recruits board-certified obesity-medicine specialists rather than general practitioners, and that distinction shows in how monitoring is handled. Compounded semaglutide is about $99 per month and compounded tirzepatide around $199, with discounts at three and twelve-month intervals. For branded meds, Mochi accepts insurance. If you want a clinician who specifically trained in metabolic disease rather than a generalist writing scripts between dermatology consults, Mochi is a strong pick at its price point.
5. Henry Meds
Speed is Henry Meds’ obvious strength. Many patients report shipping within 24 to 72 hours of approval, which almost no other service matches. Out-of-pocket compounded programs run roughly $179 to $249 in the first month. The monitoring is lighter than platforms like Form Health or Mochi, so this fits best for patients who already have a primary care physician handling their labs and just need a fast, affordable source for the medication itself.
6. Calibrate
Calibrate is built around a 12-month commitment and leans hard into behavior change coaching alongside medication. The program fee is separate from medication costs. This structure works well for patients with solid insurance who need hand-holding through prior authorizations and want structured accountability beyond just getting a script. If you want a quick, low-friction experience, Calibrate is probably not for you. If you want a program with structure, it delivers.
7. Found
Found charges about $99 per month for platform access, with medication billed separately. The model combines coaching with prescription support. It is a reasonable middle ground for patients who want some behavioral scaffolding but are not ready to commit to a full year-long program like Calibrate. Useful if coaching matters to you as much as the medication.
8. PlushCare
PlushCare is a general telehealth service with a $19.99 monthly membership. It prescribes FDA-approved branded drugs, Ozempic, Wegovy, Mounjaro, through a standard visit workflow. Labs, visits, and prescriptions are each billed separately, and the platform accepts insurance. Same-day appointments are often available. For patients who want a straightforward branded-med prescription through their insurance, PlushCare is competitively priced at the membership level. Just budget for the add-on costs.
9. Eden
Eden keeps it simple. Compounded semaglutide at roughly $149 per month, cash pay, no elaborate program structure on top. For someone who has already done their research, knows what dose they are targeting, and wants a clean monthly cost without extra fees, Eden is one of the more transparent cash-pay options. The streamlined approach means less hand-holding, so it suits patients who already have clinical support elsewhere.
10. Form Health
At about $299 per month for the program alone, plus labs and medication on top, Form Health is the most expensive service on this list. What that buys is a physician-and-registered-dietitian team working together on a personalized protocol. For well-insured patients or those with complex metabolic histories who want the most clinically intensive outpatient option available outside of a hospital system, the cost can be justified. Not the right fit for anyone working within a tight monthly budget.
11. Sesame (Success by Sesame)
Sesame operates on a marketplace model where pricing is unusually visible. Plans start around $59 per month on an annual plan and include telehealth visits and unlimited messaging. Medication is billed separately. It is one of the few platforms where you can meaningfully compare provider and medication costs before committing. Good for cost-conscious patients who want flexibility and transparency without a long-term program lock-in.
12. MEDVi
MEDVi offers compounded GLP-1 programs starting around $179 for the first month, with no contracts and no ongoing membership fee. Physician review and 24/7 support are included in that base price. For patients who are skeptical of subscription commitments, the no-contract model is a real differentiator. The 24/7 support claim is worth testing with a pre-sales question before you sign up, to verify the actual response time matches the promise.
How to Pick the Right One for You
Start with one honest question: are you paying cash or running this through insurance? If insurance is in play, Ro, Calibrate, PlushCare, and Mochi all have infrastructure built around prior authorizations and branded drugs. If you are paying cash and want compounded options, the price gap between platforms is real. FormBlends at $299 for compounded semaglutide, Henry Meds at $179-249, Eden at $149, and Mochi at $99 are not the same product at different prices. They differ in pharmacy sourcing, testing documentation, and clinical depth.
Also think about what you need beyond the GLP-1 itself. Most of these services stop at weight-loss medication. If your goals include recovery, sleep, or other protocols, a platform that can write prescriptions for a wider catalog under the same physician’s supervision saves you from cobbling together multiple providers.
The 2026 regulatory environment is not settled. The FDA’s 2026 warning letters to compounding-focused telehealth companies and the Novo Nordisk settlement are early signals, not endpoints. A service that was available and legal in January may look different by fall. Pick one with clear pharmacy sourcing, published testing, and a physician who actually knows your chart.
Do your own homework here. The decision involves your health history, your budget, and ideally a conversation with whoever manages your primary care, because no amount of reading replaces that.
Sources
- FDA: Warning letters to telehealth and compounding companies, 2026
- Drugs.com: GLP-1 drug pricing and approval status
- Examine.com: Semaglutide and tirzepatide evidence summaries
- Cleveland Clinic: Obesity medicine and GLP-1 receptor agonist overviews
- GoodRx: Retail cash prices for branded GLP-1 medications and manufacturer discount card information
- Verywell Health: Telehealth weight-loss platform reviews
- Healthline: Compounded semaglutide explainers and regulatory updates
- NEJM: Clinical trial data for semaglutide (STEP trials) and tirzepatide (SURMOUNT trials)
- FDA 503A compounding pharmacy regulatory framework (FDA.gov)
[internal: placement #1 | structure: Long list, buyer’s-guide intro, criteria section]
